Please check your internet connection and try again.
## Ecospirin (Aspirin, Enteric-Coated)
### Overview
Ecospirin is an enteric-coated formulation of aspirin, a nonsteroidal anti-inflammatory drug (NSAID) with analgesic, antipyretic, and antiplatelet properties. The enteric coating is designed to delay absorption and reduce gastric irritation.
### Primary Indications
* Pain relief (mild to moderate)
* Fever reduction
* Inflammation reduction
* Prevention of cardiovascular events (e.g., myocardial infarction, stroke) in select patient populations.
* Kawasaki disease treatment (adjunctive).
### Adult Dosing
* **Pain/Fever/Inflammation:** 325 mg to 650 mg orally every 4 hours as needed, or 500 mg to 1000 mg orally every 4 to 6 hours as needed. Maximum daily dose: 4000 mg.
* **Cardiovascular Prevention (Secondary):** 75 mg to 325 mg orally once daily.
* **Cardiovascular Prevention (Primary - in select high-risk individuals):** 75 mg to 162 mg orally once daily. (Use in primary prevention is controversial and individualized).
* **Kawasaki Disease:** Doses vary significantly based on phase of illness and presence of coronary artery aneurysms. Consult specific pediatric cardiology guidelines. Typical doses range from 30-100 mg/kg/day divided into 2-4 doses, often transitioning to a lower maintenance dose.
### Pediatric Dosing
* **Pain/Fever:** Dosing is typically based on weight. Usual dose is 10-15 mg/kg/dose orally every 4-6 hours. Maximum daily dose: 75-80 mg/kg/day, not to exceed 4000 mg/day. **Avoid aspirin in children and adolescents with viral infections due to the risk of Reye's syndrome.**
* **Kawasaki Disease:** Consult specific pediatric cardiology guidelines.
### Dose Adjustments
No specific dose adjustments are typically required for renal or hepatic impairment, however, caution is advised, especially in severe impairment, due to potential for adverse effects and accumulation.
### Contraindications
* Known hypersensitivity to aspirin, salicylates, or NSAIDs.
* Children and adolescents with viral infections (influenza, chickenpox) due to risk of Reye's syndrome.
* Active peptic ulcer disease or gastrointestinal bleeding.
* Inherited disorders of coagulation (e.g., hemophilia).
* Severe hepatic or renal impairment.
* Late pregnancy (third trimester).
### Adverse Effects
* **Gastrointestinal:** Dyspepsia, nausea, vomiting, abdominal pain, gastritis, peptic ulceration, GI bleeding.
* **Hematologic:** Increased bleeding time, bruising, petechiae, epistaxis.
* **Hypersensitivity:** Bronchospasm (especially in aspirin-sensitive asthmatics), urticaria, angioedema.
* **Renal:** Renal dysfunction, interstitial nephritis.
* **Hepatic:** Hepatotoxicity (rare).
* **Other:** Tinnitus (especially at higher doses), dizziness, headache.
### Key Drug Interactions
* **Anticoagulants (e.g., warfarin, heparin, DOACs):** Increased risk of bleeding. Monitor INR/aPTT closely; consider dose reduction or avoidance of concurrent aspirin.
* **Other NSAIDs and COX-2 Inhibitors:** Increased risk of GI toxicity and bleeding.
* **Corticosteroids:** Increased risk of GI ulceration and bleeding.
* **Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs):** Increased risk of bleeding.
* **Antihypertensives (e.g., ACE inhibitors, ARBs, diuretics):** Aspirin can reduce their antihypertensive effect.
* **Methotrexate:** Aspirin can increase methotrexate toxicity by displacing it from plasma protein binding sites and reducing renal clearance.
* **Uricosuric agents (e.g., probenecid):** Aspirin antagonizes the uricosuric effect.
* **Valproic acid:** Aspirin can displace valproic acid from protein binding sites, increasing free levels.
### Monitoring
* **Bleeding:** Monitor for signs and symptoms of GI bleeding (melena, hematemesis, abdominal pain) and easy bruising.
* **Renal function:** Particularly in patients with pre-existing renal disease or those on concurrent nephrotoxic agents.
* **Hepatic function:** Especially with long-term use or higher doses.
* **Tinnitus:** May indicate over-saturation.
### Clinical Pearls
* Enteric coating delays absorption, so onset of action may be slower compared to non-coated aspirin.
* Enteric coating does not eliminate the risk of GI bleeding entirely, especially with long-term or high-dose use.
* Do not crush or chew enteric-coated tablets, as this will destroy the coating and increase gastric irritation.
* In acute situations requiring rapid antiplatelet effect (e.g., acute coronary syndrome), non-enteric coated aspirin is preferred.
* Aspirin should be used with extreme caution in patients with asthma, nasal polyps, and history of bronchospasm due to the potential for severe reactions.
***
**Disclaimer:** This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant clinical guidelines before making any treatment decisions. Dosing may vary based on patient-specific factors and local protocols.
